Search Bar & Filters
Found 10 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating the efficacy and safety of rilvegostomig compared to pembrolizumab, both combined with platinum-based doublet chemotherapy, as a first-line treatment for patients with locally advanced or metastatic non-squamous non-small cell lung cancer NSCLC whose tumors express PD-L1 at 1% or higher. This Phase III, randomized, double-blind, global study focuses on patients without certain genetic mutations who have advanced disease not suitable for curative treatment. The trial aims to provide new treatment options for this patient group by comparing two immunotherapy approaches combined with chemotherapy. Participants receive either rilvegostomig or pembrolizumab, each given intravenously on Day 1 of every 21-day cycle, alongside platinum-based doublet chemotherapy carboplatin or cisplatin for up to four cycles. After chemotherapy, patients continue with maintenance monotherapy of their assigned immunotherapy rilvegostomig or pembrolizumab plus pemetrexed given intravenously on Day 1 of each 21-day cycle. This treatment continues until disease progression or unacceptable toxicity. Throughout the study, participants undergo regular assessments including tumor measurements by CT or MRI scans, organ and bone marrow function tests, and monitoring for side effects. Researchers will measure overall survival and progression-free survival for up to approximately six years. Patient-reported outcomes on physical functioning, quality of life, and lung cancer symptoms are also collected. Safety and pharmacokinetics of rilvegostomig are monitored to understand treatment effects and tolerability over the long term.
Actively Recruiting
Researchers are evaluating the safety and effectiveness of rilvegostomig combined with platinum-based chemotherapy compared to pembrolizumab combined with the same chemotherapy for first-line treatment of patients with locally advanced or metastatic squamous non-small cell lung cancer mNSCLC whose tumors express PD-L1. This Phase III, randomized, double-blind study involves participants whose tumors have a PD-L1 expression of 1% or higher. Participants receive either rilvegostomig or pembrolizumab intravenously on Day 1 of each 21-day cycle, combined with carboplatin and paclitaxel or nab-paclitaxel chemotherapy. Chemotherapy is given for up to 4 cycles, with nab-paclitaxel administered on Days 1, 8, and 15 of each cycle. After the chemotherapy cycles, participants continue with the assigned drug alone. Throughout the study, researchers monitor overall survival and progression-free survival for up to approximately six years. Additional assessments include response rates, duration of response, drug levels in the body, immune reactions to rilvegostomig, and patient-reported physical functioning, quality of life, and lung cancer symptoms. Participants undergo regular evaluations to assess these outcomes and safety throughout the study period.
Actively Recruiting
Researchers are evaluating the safety and effectiveness of divarasib combined with pembrolizumab compared with pembrolizumab plus pemetrexed and carboplatin or cisplatin for adults with KRAS G12C-mutated, advanced or metastatic non-squamous non-small cell lung cancer NSCLC who have not received prior treatment. This phase 3 randomized study aims to find the best first-line therapy option for this specific lung cancer type. Participants are randomly assigned to one of two groups one group receives divarasib orally once daily and pembrolizumab through intravenous infusion every three weeks, while the other group receives pembrolizumab, pemetrexed, and carboplatin or cisplatin all by intravenous infusion every three weeks. The study treatments are given as first-line therapy, and participants are monitored for up to approximately five years. During the study, participants undergo regular assessments including scans to measure tumor response, evaluations of lung cancer symptoms like cough and breathlessness, quality of life questionnaires, and monitoring for side effects. Researchers track progression-free survival and overall survival for up to about five years. Safety and symptom severity are closely followed throughout the study, providing comprehensive data on treatment impact and participant well-being.
Actively Recruiting
Researchers are conducting an international, multi-center, randomized, open-label phase III trial to compare elacestrant with standard endocrine therapy in patients with ER-positive, HER2-negative breast cancer who have relapse detected by circulating tumor DNA ctDNA. The study focuses on patients who show ctDNA in their blood but have no distant metastasis, aiming to evaluate treatment outcomes and disease progression. This trial involves a screening phase to monitor ctDNA presence and a randomized treatment phase for eligible patients. During the ctDNA screening phase, patients receive standard adjuvant endocrine therapy, such as tamoxifen or aromatase inhibitors, and undergo plasma testing every six months for up to approximately 5.7 years. Patients who test ctDNA-positive undergo imaging to rule out metastasis and, if eligible, are randomized within four weeks to either continue their current endocrine treatment or receive elacestrant at 400 mg daily orally. Treatment duration varies based on prior endocrine therapy length, lasting between 2 and 7 years. Follow-up includes frequent ctDNA testing and imaging over three years to monitor disease status. Participants will have plasma samples collected regularly during screening and follow-up. Imaging assessments such as mammograms, bone scans, and CT scans are performed to detect metastases or recurrences. Researchers will track distant metastasis-free survival and other outcomes including overall survival, disease recurrence, adverse events, and quality of life over extended periods, up to 11.7 years. The study ensures ongoing monitoring and safety evaluations throughout treatment and follow-up until study completion.
Actively Recruiting
Researchers are investigating whether taking breaks from the standard combination therapy of daratumumab, lenalidomide, and dexamethasone Dara-Rd for newly diagnosed multiple myeloma patients affects survival and quality of life. This study aims to compare continuous treatment versus planned treatment-free intervals to see if stopping therapy temporarily may reduce side effects, allow recovery from toxicity, and improve overall well-being while controlling the disease. Participants who have completed 12 cycles of Dara-Rd with at least a partial response and no signs of disease progression will be randomly assigned to one of two groups. One group will continue Dara-Rd therapy without interruption until disease progression, while the other group will stop treatment temporarily and restart it at biochemical progression, continuing until disease progression. The trial is open-label and will follow patients for several years to assess outcomes. Throughout the study, researchers will monitor participants event-free survival and progression-free survival for up to about 57 and 69 months, respectively. Additional assessments include side effect burden, patient-reported quality of life, treatment costs, treatment-free interval length, response times, and survival after second-line therapy. Regular evaluations will help determine how treatment interruption affects toxicity, dose intensity, and overall treatment outcomes over the long term.
Actively Recruiting
Researchers are evaluating a new method of stereotactic radiotherapy for treating brain metastases in this randomized phase II trial. The study compares the current standard stereotactic radiotherapy SRT delivered in one or three doses with a fractionated approach fSRT given in five doses. The goal is to find a potentially safer treatment that reduces long-term side effects like brain necrosis, which affects up to 40% of patients depending on tumor size and radiation dose. One group of participants will receive SRT in one or three sessions with doses ranging from 8 Gy up to 15-24 Gy. The other group will receive fSRT spread over five sessions with doses of 7 Gy up to 35 Gy, or for brain stem metastases, five sessions of 6 Gy up to 30 Gy. This treatment phase compares these two radiation schedules to assess differences in safety and tumor control. Participants will be monitored for survival, side effects, and quality of life for two years after treatment. Researchers will track the occurrence of brain necrosis or tumor recurrence, need for additional treatments, brain recurrences, corticosteroid and anti-epileptic drug use, and any grade 2 or higher toxicities. This thorough follow-up includes patient-reported outcomes and medical assessments to understand the treatments impact over time.
Actively Recruiting
Researchers are evaluating treatments for patients with locally recurrent rectal cancer in this multicenter, open-label, randomized phase III clinical trial. The study compares two approaches for neoadjuvant treatment before surgery induction chemotherapy followed by chemoradiotherapy and surgery versus chemoradiotherapy and surgery alone. The purpose is to determine whether adding induction chemotherapy improves surgical outcomes and cancer control. Participants will be randomly assigned to one of two groups. The experimental group receives induction chemotherapy using either CAPOX, FOLFOX, or FOLFIRI regimens, followed by chemoradiotherapy and then surgery. The control group receives chemoradiotherapy followed by surgery without induction chemotherapy. Radiotherapy doses vary based on prior treatment history, and surgery type depends on tumor location. Intraoperative radiotherapy is optional. During the study, patients will undergo MRI and clinical assessments to confirm resectability and monitor response to treatment. Researchers will assess the proportion of patients with clear surgical margins within one month of surgery, along with long-term outcomes such as survival and recurrence over five years. They will also evaluate treatment toxicity, compliance, surgical complications, radiological response, and quality of life at multiple time points. Follow-up includes monitoring up to five years after treatment to capture disease progression and survival.
Actively Recruiting
Researchers are studying women with node-positive breast cancer who receive neoadjuvant systemic therapy NST, which includes chemotherapy with or without immunotherapy. The study aims to understand the safety and quality of life effects of using less invasive methods compared to more invasive axillary staging and treatment after NST. This is important because patients whose lymph nodes show no remaining cancer after NST may not benefit from extensive lymph node removal, but more evidence is needed about the safety and impact of less invasive approaches. This multicenter observational study collects detailed information on patients treated with NST for node-positive breast cancer. It gathers data about the cancer, staging methods before and after NST, and treatment details from medical records. Patients complete questionnaires about their quality of life at diagnosis, and then 1 and 5 years later. The study database is maintained by the Netherlands Cancer Registry and aims to inform future treatment guidelines. Participants provide information through patient-reported outcome measures and undergo regular clinical follow-up to monitor disease-free survival, breast cancer-specific survival, overall survival, and rates of cancer recurrence in the lymph nodes over five years. Quality of life is assessed using several validated tools at baseline and during follow-up. The study results will help balance treatment decisions between less and more invasive options and support shared decision making for women with this breast cancer type.
Actively Recruiting
The trial investigates treatments for patients with high-risk locally advanced rectal cancer. It compares triplet induction chemotherapy FOLFOXIRI with doublet induction chemotherapy CAPOXFOLFOX, both followed by chemoradiotherapy and then either surgery or a watch-and-wait approach. The study aims to find out if the triplet therapy leads to higher complete response rates, better quality of life, and improved long-term outcomes despite a potential increase in side effects. Participants in one group receive FOLFOXIRI chemotherapy given in cycles every two weeks, followed by chemoradiotherapy that includes radiation combined with capecitabine or an alternative drug if needed. The other group receives CAPOX or FOLFOX chemotherapy followed by the same chemoradiotherapy regimen. After these treatments, patients either have surgery or enter a watch-and-wait follow-up if their cancer shows complete response. Imaging scans are done at multiple points to evaluate treatment response, and surgery timing depends on these results. During the study, participants undergo regular imaging with MRI and CT scans, endoscopies, and clinical exams to assess tumor response. Quality of life and work productivity questionnaires are completed at baseline and after treatments. Researchers monitor treatment toxicity, dose adjustments, surgical outcomes, and long-term survival and recurrence over several years. Follow-up includes close monitoring for tumor regrowth or recurrence, especially for those in the watch-and-wait group, with visits scheduled up to five years after treatment.
Actively Recruiting
Researchers are evaluating a combined treatment approach for men with high risk prostate cancer to determine if it is safe to use several optimized therapies together. This includes delivering a higher dose of radiation to the tumor while irradiating the prostate and lymph nodes more intensively but with fewer hospital visits. The study aims to reduce androgen deprivation therapy as much as possible to minimize side effects while comparing cancer outcomes and treatment toxicity. The treatment being studied involves hypo fractionated pelvic radiotherapy with a focal boost to the primary tumor in the prostate, along with elective lymph node irradiation and minimized use of androgen deprivation therapy. This approach combines recent advances shown to improve outcomes individually but not previously combined into one comprehensive treatment. The study is designed as a prospective cohort with a matched control group. Participants will undergo regular clinical follow-up without additional tests or visits beyond standard care. Researchers will assess biochemical recurrence-free survival over 5 years and monitor late gastrointestinal and genitourinary side effects, including erectile dysfunction, at 6 months and 2 years. Secondary outcomes include metastasis-free survival, overall survival, and patterns of cancer recurrence. The estimated risks from combining these treatments are considered very limited, and the overall burden for participants is low.